Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. Volume 10 of the series continues to present novel information about new and interesting approaches to treat common neurological disorders, with a focus on neurodegeneration and pain medicine. The volume presents 7 detailed reviews in total. - Neurodegenerative disease: prevention and treatment through plant extracts therapy - Emerging novel approaches and recent advances in Parkinson’s disease treatment and diagnosis - Neurotrophic factors to combat neurodegeneration - Neural bases of executive function in ADHD children as assessed using FNIRS - Modulation of mesenchymal stem cells, glial cells and the immune system by oligodeoxynucleotides as a novel multi-target therapeutic approach against chronic pain - Chronic pain: focus on anticonvulsants - A review of the impact of testosterone on brain and aging-related decline in brain behavioural function

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in neurology and allied disciplines. The twelfth volume of this series features these reviews: Chapter 1: Recent Drugs Tested in Clinical Trials for Alzheimer's and Parkinson's Diseases Treatment: Current Approaches in Tracking New Drugs Chapter 2: Neurobiology of Placebo: Interpreting Its Evolutionary Origin, Meaning, Mechanisms, Monitoring, and Implications in Therapeutics Chapter 3: Role of Gut Microbiota in Neuroinflammation and Neurological Disorders Chapter 4: The Role of Age in Pediatric Tumors of the Central Nervous System Chapter 5: Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities Chapter 6: Progress on the Development of Oxime Derivatives as a Potential Antidote for Organophosphorus Poisoning Readership Pharmaceutical scientists, clinical researchers, medical consultants and allied healthcare professionals interested in neuropharmacology and neurology

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The eleventh volume of this series features reviews that cover the following topics related to the treatment of a variety of CNS disorders, related diseases, and basic research: - The Multi-target Directed Ligands candidate (MTDLs) prototypes for neurodegenerative diseases - Drugs for relapse prevention in addiction - Neuroprotective activities of cinnamic acids and their derivatives in neurodegenerative disorders - Phytosome for targeted delivery of natural compounds in treating alzheimer's disease - Physical activity as a non-pharmacologic method for treatment of alzheimer’s disease

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The seventh volume of this series features reviews that cover the following topics related to the treatment of neurodegenerative diseases, epilepsy and stroke: -Fatty Acid Amides as a New Potential Therapeutic Agent in Multiple Sclerosis -Epileptic Seizures Detection Based on Non-Linear Characteristics Coupled with Machine Learning Techniques -Hampering Essential Tremor Neurodegeneration in Essential Tremor: Present and Future Directions -The Potential Therapeutic Role of the Melatoninergic System in Treatment of Epilepsy and Comorbid Depression -Modeling Neurodegenerative Diseases Using Transgenic Model of Drosophila -Genetic Basis in Stroke Treatment: Targets of Potent Inhibitors

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The eighth volume of this series features reviews that cover the following topics related to the treatment of a variety of CNS disorders, related diseases and basic research: - Emerging Innovative Therapies of Spinal Muscular Atrophy: Current Knowledge and Perspectives - Obesity Induced by The Neurological Drugs - Molecular Mechanism of Nervous System Disorders and Implications for New Therapeutic Targets - Glioma Imaging and Novel Agents - Screening Models for Neuroleptic Drug-Induced Hyperprolactinemia: A Mini-Review.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The ninth volume of this series features reviews that cover the following topics related to the treatment of a different CNS disorders, related diseases and basic neuropharmacology research: - Integrating imaging and microdialysis into systems neuropharmacology - Depression heterogeneity and the potential of a transdiagnostic and dimensional approach to identify biologically relevant phenotypes - CAR-T cells in brain tumors and autoimmune diseases – from basics to the clinic - Revaluation of thyrotropin-releasing hormone and its mimetics as candidates for treating a wide range of neurological and psychiatric disorders - Natural BACE1 inhibitors: promising drugs for the management of Alzheimer’s disease - The possibilities of safe lithium therapy in the treatment of neurological and psychoemotional disorders - Pharmacotherapy of multiple sclerosis and treatment strategies

A Blueprint for the Hard Problem of Consciousness addresses the fundamental mechanism that allows physical events to transcend into subjective experiences, termed the Hard Problem of Consciousness. Consciousness is made available as the abstract product of self-referent realization of information by strange loops through the levels of processing of the brain. Readers are introduced to the concept of the Hard Problem of Consciousness and related concepts followed by a critical discourse of different theories of consciousness. Next, the author identifies the fundamental flaw of the Integrated Information Theory (IIT) and proposes an alternative that avoids the cryptic intelligent design and panpsychism of the IIT. This author also demonstrates how something can be created out of nothing without resorting to quantum theory, while pointing out neurobiological alternatives to the bottom-up approach of quantum theories of consciousness. The book then delves into the philosophy of qualia in different physiological knowledge networks (spatial, temporal and olfactory, cortical signals, for example) to explain an action-based model consistent with the generational principles of Predictive Coding, which maps prediction and predictive-error signals for perceptual representations supporting integrated goal-directed behaviors. Conscious experiences are considered the outcome of abstractions realized out of map overlays and provided by sustained oscillatory activity. The key feature of this blueprint is that it offers a perspective of the Hard Problem of Consciousness from the point of view of the subject; the experience of ‘being the subject’ is predicted to be the realization of inference inversely mapped out of hidden causes of global integrated actions. The author explains the consistencies of his blueprint with ideas of the Global Neuronal Workspace and the Adaptive Resonance Theory of consciousness as well as with the empirical evidence supporting the Integrated Information Theory. A Blueprint for the Hard Problem of Consciousness offers a unique perspective to readers interested in the scientific philosophy and cognitive neuroscience theory in relation to models of the theory of consciousness.